Completed
Beta-Blocker Heart Attack Trial (BHAT)
Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2016-07-12
N/A
Participants Needed
N/A
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine whether the regular administration of the beta-blocker drug propranolol to people who had had at least one documented myocardial infarction would result in a significant reduction of mortality from all causes over the follow-up period. Eligible volunteer patients were recruited to participate in a double-blind clinical trial within 21 days after the onset of the acute event. One-half of the patients were randomly assigned to a beta-blocking drug (propranolol) and one-half to a placebo. The trial also evaluated the effect of propranolol on incidences of coronary heart disease mortality, sudden cardiac death, and nonfatal myocardial infarction plus coronary heart disease mortality in persons with documented previous myocardial infarction.
CONDITIONS
Official Title
Beta-Blocker Heart Attack Trial (BHAT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
Men and women, ages 30 to 69. Documented myocardial infarction.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
N/A
Primary Purpose
PREVENTION
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here